CoChat

Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes

Open access

The DOI matches its Crossref record, with a small difference in title or year; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Background: Nonarteritic anterior ischemic optic neuropathy (NAION) is an untreatable condition often causing severe and irreversible visual loss in the affected eye. As it has recently been implied that the use of semaglutide associates with NAION, the aim of the present study was to evaluate this risk prospectively in all persons with type 2 diabetes (T2D) in Denmark. Methods: In a five-year longitudinal cohort study, we identified all persons with T2D in Denmark ( n = 424,152) between 2018 and 2024. Patients were stratified according to exposure ( n = 106,454) or non-exposure ( n = 317,698) to once-weekly semaglutide, and incidence rates and hazard ratios (HR) of NAION were estimated in a multivariable Cox proportional hazard regression model. Results: At baseline, median age and hemoglobin A1c were 65 years and 50 mmol/mol, and 54·5% were male. During 1,915,120 person-years of observation, 218 persons developed NAION. Semaglutide exposure was associated with a higher incidence rate (0·228 vs. 0·093 per 1000 person-years, p < 0·001) and independently predicted a higher risk of upcoming NAION (HR 2·19, 95% confidence interval 1·54 − 3·12), even when multiple other factors were taken into account. Overall, 67 persons exposed to semaglutide developed NAION with a median time from first prescription to event of 22·2 months (interquartile range 10·2–37·8 months). Conclusions: During five years of observation of all persons with T2D in Denmark, use of once-weekly semaglutide independently more than doubled the risk of NAION. Given the irreversible nature of NAION, it is important to acknowledge this risk, and upcoming studies should aim to identify high-risk subgroups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40942-024-00620-x

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Number of first-time episodes of nonarteritic anterior ischemic optic neuropathy (NAION) and persons with type 2 diabetes (T2D) redeeming at least one prescription of once-weekly semaglutide (Ozempic®) between January 1, 2010, and June 30, 2024
Fig. 1 Number of first-time episodes of nonarteritic anterior ischemic optic neuropathy (NAION) and persons with type 2 diabetes (T2D) redeeming at least one prescription of once-weekly semaglutide (Ozempic®) between January 1, 2010, and June 30, 2024CC BY · PubMed Central
Fig. 2 Time from redemption of first prescription of once-weekly semaglutide (Ozempic®) to first event of nonarteritic anterior ischemic optic neuropathy (NAION) in the 67 persons with type 2 diabetes patients, who were exposed to semaglutide and developed at least one event of NAION in 2018–2024. Box and whisker plot includes median time, interquartile range and range
Fig. 2 Time from redemption of first prescription of once-weekly semaglutide (Ozempic®) to first event of nonarteritic anterior ischemic optic neuropathy (NAION) in the 67 persons with type 2 diabetes patients, who were exposed to semaglutide and developed at least one event of NAION in 2018–2024. Box and whisker plot includes median time, interquartile range and rangeCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 1

  1. World Health O. International classification of disease and related health problems, Tenth revision (ICD 10). Geneva: World Health Organization; 1992.

Cited by

See all 87

Metadata

Authors
Grauslund, J., Taha, A. A., Molander, L. D., Kawasaki, R., Möller, S., Højlund, K., & Stokholm, L.
Affiliations
  • University of Southern Denmark (DK)
  • Odense University Hospital (DK)
Corresponding author
Grauslund, Jakob
Venue
International Journal of Retina and Vitreous
Published
2024-12-18
Volume
10
Issue
1
Pages
97-97
ISSN
2056-9920 (ISSN-L)
OpenAlex
W4405516842
Cited by
79
References
22
Citations by year
2026: 38 · 2025: 41
FWCI
25.88
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Retina and Vitreous (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
Keywords
semaglutide, nonarteritic anterior ischemic optic neuropathy, type 2 diabetes, drug safety, adverse drug reactions, vision loss, incidence, risk factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. https://app.cochat.ai/papers/10.1186/s40942-024-00620-x
The paper
Grauslund, J., Taha, A. A., Molander, L. D., Kawasaki, R., Möller, S., Højlund, K., & Stokholm, L. (2024). Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. International Journal of Retina and Vitreous. https://doi.org/10.1186/s40942-024-00620-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.